Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

about

Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.Application of bee venom and its main constituent melittin for cancer treatment.Antimicrobial Activity of Bee Venom and Melittin against Borrelia burgdorferi.

P2860

Q38768426-02DF0D29-3790-4BBB-921E-24DDECC435A1 Q38966140-214C0B37-889C-4519-8636-A4D5EB549B83 Q47098465-EAC30E30-5048-4BB8-9A2D-FDC794754E84

P2860

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

Item

http://www.wikidata.org/entity/Q36955437

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

@en

type

Item

label

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

@en

prefLabel

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

@en

P1476

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

@en

P2093

Bin Wang

http://www.w3.org/2001/XMLSchema#string

Guirong Sun

http://www.w3.org/2001/XMLSchema#string

Haitao Wang

http://www.w3.org/2001/XMLSchema#string

Linjie Liu

http://www.w3.org/2001/XMLSchema#string

Mingjun Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2014

Cancer and the tumor microenvironment: a review of an essential relationship.

Interleukin-2 in the treatment of renal cancer.

Induced expression of melittin, an antimicrobial peptide, inhibits infection by Chlamydia trachomatis and Mycoplasma hominis in a HeLa cell line.

Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.

Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway.

Endotoxin-induced serum factor that stimulates gamma interferon production.

Immunotherapy of cancer in 2012.

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Cytokine-based therapy and biochemotherapy for advanced melanoma.

P2888

s12967-016-0910-0

P304

155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12967-016-0910-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27246873

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

4888606

http://www.w3.org/2001/XMLSchema#string

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

about

P2860

P2860

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932